Arcellx, Inc. Common Stock (ACLX) is a publicly traded Healthcare sector company. As of May 21, 2026, ACLX trades at $115.07 with a market cap of $6.73B and a P/E ratio of -28.27. ACLX moved +0.03% today. Year to date, ACLX is +62.44%; over the trailing twelve months it is +80.62%. Its 52-week range spans $47.86 to $115.13. Analyst consensus is hold with an average price target of $112.45. Rallies surfaces ACLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Gilead’s $7.8B Arcellx Purchase Is Third Oncology Acquisition: Gilead Sciences acquired Arcellx in February for $7.8 billion as its third oncology-focused buyout this year, following a $5 billion deal for Tubulis and a $2 billion-plus acquisition of Ouro Medicines. The spree aims to strengthen Gilead’s antibody–drug conjugate pipeline and offset patent expiries on its COVID-19 treatment.
| Metric | Value |
|---|---|
| Price | $115.07 |
| Market Cap | $6.73B |
| P/E Ratio | -28.27 |
| EPS | $-4.07 |
| Dividend Yield | 0.00% |
| 52-Week High | $115.13 |
| 52-Week Low | $47.86 |
| Volume | 16.12M |
| Avg Volume | 0 |
| Revenue (TTM) | $22.29M |
| Net Income | $-228.93M |
| Gross Margin | 0.00% |
18 analysts cover ACLX: 0 strong buy, 7 buy, 11 hold, 0 sell, 0 strong sell. Consensus rating is hold. Average price target: $112.45.